Citius Oncology (CTOR) News Today $1.72 +0.05 (+2.99%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$1.72 +0.01 (+0.29%) As of 10/24/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CTOR Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Citius Oncology (NASDAQ:CTOR) Stock Price Up 1.2% - What's Next?October 24 at 3:33 AM | marketbeat.comCitius Oncology Prepares LYMPHIR Launch for Q4 2025October 23 at 9:09 PM | msn.comCitius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 ConferencesOctober 17, 2025 | prnewswire.comCitius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™October 16, 2025 | prnewswire.comCitius Oncology's (CTOR) "Sell (D-)" Rating Reaffirmed at Weiss RatingsOctober 9, 2025 | marketbeat.comCitius Oncology signs distribution agreement for Lymphir in Southern EuropeOctober 7, 2025 | msn.comCitius Oncology Establishes International Access to LYMPHIR™ via Named Patient Programs in Southern EuropeOctober 7, 2025 | prnewswire.comCitius Oncology, Inc. (NASDAQ:CTOR) Short Interest Down 55.2% in SeptemberOctober 3, 2025 | marketbeat.comCitius Oncology (CTOR) Price Target Increased by 100.00% to 6.12October 1, 2025 | msn.comCitius Oncology, Inc. (NASDAQ:CTOR) stock most popular amongst public companies who own 79%, while individual investors hold 14%September 26, 2025 | finance.yahoo.comMaxim upgrades Citius Oncology to Buy, sees its capital needs being metSeptember 23, 2025 | msn.comCitius Oncology upgraded to Buy from Hold at MaximSeptember 23, 2025 | msn.comMaxim Group Upgrades Citius Oncology (CTOR)September 23, 2025 | msn.comCitius Oncology (NASDAQ:CTOR) Raised to "Buy" at Maxim GroupSeptember 23, 2025 | marketbeat.comCitius Oncology Issues Warrants in Private PlacementSeptember 19, 2025 | tipranks.comCitius Oncology (NASDAQ:CTOR) Shares Up 3.3% - Still a Buy?September 12, 2025 | marketbeat.comCitius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private PlacementSeptember 10, 2025 | prnewswire.comCitius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private PlacementSeptember 9, 2025 | prnewswire.comCitius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR LaunchAugust 22, 2025 | prnewswire.comCitius Oncology (NASDAQ:CTOR) Shares Up 3.6% - Time to Buy?August 20, 2025 | marketbeat.comCitius Oncology Conducts Public Offering of StockAugust 18, 2025 | tipranks.comCitius Oncology (NASDAQ:CTOR) Releases Earnings ResultsAugust 14, 2025 | marketbeat.comCitius Oncology Beats Fiscal Q3 EPSAugust 13, 2025 | theglobeandmail.comCitius Oncology, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business ...August 12, 2025 | gurufocus.comCitius Oncology, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business UpdateAugust 12, 2025 | prnewswire.comCitius Oncology (NASDAQ:CTOR) Upgraded to "Hold" at Wall Street ZenJuly 26, 2025 | marketbeat.comCitius Oncology Announces Closing of $9.0 Million Public OfferingJuly 17, 2025 | prnewswire.comCitius Oncology Announces Pricing of $9.0 Million Public OfferingJuly 16, 2025 | prnewswire.comCitius Oncology Shares Climb Following Expansion of LYMPHIR Distribution NetworkJuly 15, 2025 | msn.comCitius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with CencoraJuly 15, 2025 | prnewswire.comCitius Oncology launches $15M equity and warrant offering; shares downJuly 15, 2025 | msn.comCitius Oncology, Inc. Common Stock (CTOR) FinancialsJuly 11, 2025 | nasdaq.comCitius Oncology (NASDAQ:CTOR) Stock Price Up 1.9% - Should You Buy?July 5, 2025 | marketbeat.comCitius Oncology Regains Nasdaq Compliance June 2025June 27, 2025 | tipranks.comCitius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025June 17, 2025 | prnewswire.comCitius Oncology stock soars on distribution dealJune 9, 2025 | in.investing.comCitius Oncology (NASDAQ:CTOR) Trading Up 3.4% - Here's WhyJune 6, 2025 | marketbeat.comMaxim Group Reiterates "Hold" Rating for Citius Oncology (NASDAQ:CTOR)May 25, 2025 | marketbeat.comMaxim Group Downgrades Citius Oncology (CTOR)May 24, 2025 | msn.comCitius Oncology (NASDAQ:CTOR) Trading Down 2.8% - Should You Sell?May 17, 2025 | marketbeat.comCitius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business UpdateMay 14, 2025 | prnewswire.comCitius Oncology, Inc. (NASDAQ:CTOR) Is Expected To Breakeven In The Near FutureMay 7, 2025 | finance.yahoo.comCitius Oncology, Inc. Common Stock (CTOR) Institutional HoldingsMay 5, 2025 | nasdaq.comCitius Pharmaceuticals to Present at the Jefferies Global Healthcare ConferenceMay 5, 2025 | prnewswire.comWall Street Set to Open Lower Monday as Investors Gird for More Tariffs, Await Key Manufacturing DataApril 1, 2025 | msn.comCitius Oncology (NASDAQ:CTOR) Shares Up 39.8% - Still a Buy?April 1, 2025 | marketbeat.comInvestors Brace for 'Liberation Day' as US Futures Trend Sharply Lower in Monday's PremarketMarch 31, 2025 | msn.comCitius Oncology (NASDAQ:CTOR) Stock Price Down 2.5% - What's Next?February 22, 2025 | marketbeat.comCTOR Citius Oncology, Inc.February 20, 2025 | seekingalpha.comCitius Oncology (NASDAQ:CTOR) Issues Earnings ResultsFebruary 15, 2025 | marketbeat.com Get Citius Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CTOR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CTOR Media Mentions By Week CTOR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CTOR News Sentiment▼0.500.93▲Average Medical News Sentiment CTOR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CTOR Articles This Week▼41▲CTOR Articles Average Week Get the Latest News and Ratings for CTOR and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Citius Oncology and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies MoonLake Immunotherapeutics News Today Bicycle Therapeutics News Today KalVista Pharmaceuticals News Today Compass Therapeutics News Today Olema Pharmaceuticals News Today Prothena News Today Rapt Therapeutics News Today Esperion Therapeutics News Today Corvus Pharmaceuticals News Today Inhibrx Biosciences News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CTOR) was last updated on 10/25/2025 by MarketBeat.com Staff From Our PartnersIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored$4,200 gold is nice ... but here’s what most gold bugs are missingGold just surged past $4,200, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
